ライフサイエンスコーパス: lozenge

1 ion nicotine replacement therapy (patch plus lozenge).

2 were administered placebo and nicotine (2-mg lozenge).

3 placement therapy of a 21-mg patch plus 2-mg lozenge.

4 s (So) transcriptional targets dachshund and lozenge.

5 expression was autoregulated by Serpent and Lozenge.

6 ell lineage is dependent on both Serpent and Lozenge.

7 equired Serpent but also the RUNX homologue, Lozenge.

8 ty of Runt and a second Runt domain protein, Lozenge.

9 The control group received SRP and placebo lozenges.

10 more of varenicline or to a 42-mg patch and lozenges.

11 chers for low-cost patches along with gum or lozenges.

12 root planing (SRP) and probiotic-containing lozenges.

13 Zinc lozenges, 10 mg, orally dissolved, 5 times a day (in gra

14 events was lower for the NP (18.2%) than the lozenge (33.3%) or gum (18.8%).

15 ower by 13.0% (95% CI, -13.7% to -12.3%) for lozenges, 6.4% (95% CI, -7.3% to -5.5%) for patches, and

16 Lozenge, a Runt/AML1/CBFA1-like transcription factor, de

17 Lozenge, a Runx protein homologue, and Glial cells missi

18 gulation of u-shaped was delayed until after lozenge activation, consistent with our previous results

19 , we found that precursor cells downregulate lozenge and divide stereotypically to generate three-cel

20 esis, the acute myeloid leukemia 1 homologue Lozenge and Glial cells missing are required for the pro

21 The NP, lozenge and gum mean C(max) values were 8.5, 8.3 and 4.4

22 nuclear protein that co-localizes with both Lozenge and Runt in the eye imaginal disc.

23 Furthermore, expression of Lozenge and SrpNC, a Srp isoform with N- and C-terminal

24 the hematopoietic RUNX transcription factor lozenge and the subsequent production of crystal cells,

25 ns for the biological activities of Runt and Lozenge, and further suggest that Brother protein functi

26 e orally treated with the holoBLG or placebo lozenge, and immunologically analysed after systemic all

27 lumes in millions of pieces of nicotine gum, lozenge, and patch brands before and during the COVID-19

28 two genes encoding alpha-subunits, runt and lozenge, and two genes encoding beta-subunits, Big broth

29 Here we show that Srp, Lozenge, and U-shaped interact in different combinations

30 crystal cell lineage commitment by Serpent, Lozenge, and U-shaped.

31 6.2) million gum pieces, 51.9 (31.6) million lozenges, and 2.0 (1.1) million patches.

32 otine pouches; nontherapeutic nicotine gums, lozenges, and tablets; and nicotine gummies-have rapidly

33 xpression of SerpentNC with U-shaped blocked lozenge- and u-shaped-lacZ reporter-gene activity.

34 re, we formulated for clinical translation a lozenge as food for special medical purposes (FSMP) usin

35 im was to assess the effect of a bupivacaine lozenge as topical pharyngeal anesthetic compared with s

36 Lozenge belongs to the Runx class of transcription facto

37 ctor 4 (RUNX4), the orthologue of Drosophila Lozenge, bound to the RUNT binding motif in the promoter

38 ease bupropion, nicotine patch plus nicotine lozenge, bupropion plus nicotine lozenge, or placebo.

39 While the nicotine lozenge, bupropion, and bupropion plus lozenge produced

40 A bupivacaine lozenge compared with a lidocaine spray proved to be a s

41 Participants took one lozenge containing 12.8 mg of zinc acetate or placebo ev

42 Participants took 1 lozenge containing 13.3 mg of zinc (as zinc acetate) or

43 Lozenges containing L. reuteri may be a useful supplemen

44 Big brother functions with Lozenge during cell fate specification in the eye, and i

45 e zinc group (n = 50) received lozenges (one lozenge every 2 hours while awake) containing 13.3 mg of

46 oss-regulatory sub-circuit that can modulate lozenge expression.

47 thod is successfully employed in candies and lozenges for sore throat treatment.

48 ment located within the second intron of the lozenge gene is responsible for its eye-specific express

49 th proteins is mediated by regulation of the lozenge gene.

50 icotine patch with a shorter-acting product (lozenge, gum, inhaler, or nasal spray) and extend treatm

51 analysis was to investigate whether xylitol lozenges had a differential effect on cumulative caries

52 This lozenge has been optimised to allow easy manufacture and

53 treatment, and zinc gluconate glycine (ZGG) lozenges have been shown to reduce the duration of cold

54 Zinc lozenges have been used for treatment of the common cold

55 ed to additionally use NRT (2 mg) or placebo lozenges if there was an urge to smoke.

56 ng experiments demonstrate the importance of lozenge in defining the mosquito oenocytoid cell fate.

57 al of the combination of varenicline and NRT lozenges in hospitalized adult daily smokers, the combin

58 h TIMP-1 levels may indicate the role of the lozenges in reduction of inflammation-associated markers

59 ted the effectiveness of xylitol vs. placebo lozenges in the prevention of dental caries in caries-ac

60 Lozenge is not itself a cell-specific transcription fact

61 The lozenge is stable in healthy human urine and can be ster

62 The consumption of probiotic L. reuteri-lozenges is an efficacious measure to improve and mainta

63 the prevalence of adverse effects with zinc lozenges is high.

64 An optimised biosensor "lozenge" is presented here, which is able to detect impe

65 e randomized to receive either a bupivacaine lozenge (L-group, n = 51) or lidocaine spray (S-group, n

66 oietic cis-regulatory module and showed that lozenge-lacZ reporter-gene expression was autoregulated

67 The lozenge-like utrophin CH domain densities localized to t

68 he activity of the RUNX transcription factor Lozenge (LZ) during development of the crystal cells, on

69 the activity of the Drosophila Runx protein Lozenge (Lz) during pupal development causes a decrease

70 Lozenge (Lz) is a multifunctional transcription factor t

71 The transcription factor Lozenge (Lz) is expressed exclusively in second wave cel

72 demonstrate that binding of the Runx protein Lozenge (Lz) is required for enhancers to be competent t

73 compared with loss-of-function phenotypes of lozenge (lz), an AML1 homolog expressed during Drosophil

74 y expressed transcription factors encoded by lozenge (lz), Drop (Dr) and AP-2.

75 and negative regulation by the Runx protein Lozenge (Lz).

76 tion factors, such as the AML1-like protein, Lozenge (Lz).

77 Here, we identified a lozenge minimal hematopoietic cis-regulatory module and

78 Moreover, we find that the effects of lozenge mutations on eye development are suppressed by e

79 4); and (3) C-NRT (nicotine patch + nicotine lozenge; n = 421).

80 the selection between a Lozenge-positive and Lozenge-negative state.

81 zed to 1 of 6 treatment conditions: nicotine lozenge, nicotine patch, sustained-release bupropion, ni

82 ction, only the nicotine patch plus nicotine lozenge (odds ratio, 2.34, P < .001) produced significan

83 Patients in the zinc group (n = 50) received lozenges (one lozenge every 2 hours while awake) contain

84 ric complexes between Big brother and either Lozenge or Runt.

85 bricants, saliva substitutes, and sugar-free lozenges or chewing gum.

86 us nicotine lozenge, bupropion plus nicotine lozenge, or placebo.

87 owed similar nicotine bioavailability to the lozenge (p = 0.6526 (C(max)), p = 1.0000 (AUC(0-T))), an

88 that contributes to the selection between a Lozenge-positive and Lozenge-negative state.

89 otine lozenge, bupropion, and bupropion plus lozenge produced effects that were comparable with those

90 n previous research, the nicotine patch plus lozenge produced the greatest benefit relative to placeb

91 lso required for activation, and overlapping Lozenge protein distribution and DER signaling establish

92 Binding of the cell-specific Lozenge protein is also required for activation, and ove

93 The Lozenge protein is expressed in the nuclei of the cells

94 mice, only supplementation with the holoBLG lozenge reduced clinical reactivity to BLG and Bet v 1,

95 Finally, we showed that lozenge reporter-gene activity increased in a u-shaped m

96 ipulating activity of a co-operating factor, Lozenge/Runx, we showed that it can help facilitate thes

97 Coexpression of Srp and Lozenge synergistically activated the crystal cell progr

98 The FSMP lozenge targeted antigen presenting cells and dampened i

99 oup (n = 50) received similarly administered lozenges that contained 5% calcium lactate pentahydrate

100 Compared with the lozenge, the NP demonstrated greater product satisfactio

101 that together with the transcription factor Lozenge, the nuclear effectors of the EGFR and Notch sig

102 with the pre-patterning transcription factor Lozenge, these factors work in a highly combinatorial ma

103 lations, including toothpastes, mouthwashes, lozenges, throat and nasal sprays, and as biocides.

104 actor Serpent interacts with the RUNX factor Lozenge to activate the crystal cell program, whereas Se

105 d randomly provided with a blinded supply of lozenges to be consumed twice daily for the following 42

106 d for three 4 mg nicotine products (NP, gum, lozenge) under fasting conditions.

107 ion counseling in jail, a supply of nicotine lozenges upon release, and up to 4 telephone counseling

108 In 13 of 34 nicotine gum or lozenge users from both studies, total NNN at one or mor

109 of combination nicotine patch plus nicotine lozenge vs 2 weeks of nicotine patch), (3) text-message

110 The lozenge was tested in vitro and in a therapeutical BALB/

111 Administration of zinc lozenges was associated with reduced duration and severi

112 Administration of zinc lozenges was associated with reduced duration and severi

113 nity-based, randomized controlled trial, ZGG lozenges were not effective in treating cold symptoms in

114 The transcription factor Lz (Lozenge), which resembles human AML1 (acute myeloid leuk

115 tion of the Runx family transcription factor Lozenge, which is a key regulator of crystal cell fate.

116 Clinically, the lozenge will provide a visible indication of impending c